Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Online-Ressource
    Online-Ressource
    Wiley ; 1988
    In:  European Journal of Immunology Vol. 18, No. 11 ( 1988-11), p. 1839-1842
    In: European Journal of Immunology, Wiley, Vol. 18, No. 11 ( 1988-11), p. 1839-1842
    Kurzfassung: In adoptive immunotherapy the lymphokine‐activated killer (LAK) cells, known to be cytotoxic to many tumor cell lines, are injected i.v. into tumor‐bearing animals or cancer patients. However, in addition to a significant reduction in tumor masses, complications occur in many cases, most severe of which are the vascular leak syndrome and hypotension. In this report we show that LAK cells are also cytotoxic to normal vascular endothelial cells, which may partly contribute to these complications. Incubation of the endothelial cells with interferon‐gamma (IFN‐Γ), but not with inter‐leukin 1 (IL1) or tumor necrosis factor, protects the endothelial cells from LAK‐mediated lysis in a dose‐ and time‐dependent manner. The protective effect is abolished by monoclonal antibody against IFN‐γ. However, the IFN‐γ treatment does not protect LAK‐sensitive tumor cell lines from LAK‐mediated lysis. Concomitantly IFN‐γ also induces both class I and class II antigens on endothelial cells. The induction of these major histocompatibility complex (MHC) antigens does not explain the protective effect: timewise, the protection is complete already within 24 h after addition of IFN‐γ to endothelial cell culture, whereas the induction of MHC antigens peaks at 72 h, and antibodies against these antigens are not able to abolish the protective effect.
    Materialart: Online-Ressource
    ISSN: 0014-2980 , 1521-4141
    URL: Issue
    RVK:
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 1988
    ZDB Id: 1491907-2
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie auf den KOBV Seiten zum Datenschutz